UNSPSC 51283924: Sulfamoxole

This classification denotes an anti-infective agent and sulfanilamide with the molecular formula C11H13N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HGG82XE020, chemically known as 4,5-dimethyl-2-sulfanilamidooxazole but generally known as sulfamoxole, which bears US NIH Compound Identifier 12894. European Medicines Agency schedules Sulfamoxole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10717MIG.

UNSPSC 51283924 Sulfamoxole, a Commodity code, shows minimal recent alignment with state and local procurement activity. While the code nominally identifies a specific sulfonamide antibiotic, recent solicitations tagged under it diverge substantially: the most prominent opportunity—Seminole County, Florida's IFB 60459723LAS—seeks naloxone and drug deactivation systems for community health initiatives, which bear no pharmaceutical relationship to sulfamoxole. The other three recent opportunities tracked under this code address broader pharmaceutical and medical supply categories: generic multi-source pharmaceuticals and OTC products through Minnesota's MMCAP cooperative vehicle, a Texas HHS direct-to-manufacturer prescription program RFI, and Tampa Fire Department medical and first aid supplies including respiratory equipment and cardiac monitoring devices. None of these solicitations explicitly request sulfamoxole or related sulfonamide compounds, suggesting either a classification mismatch in the source data or minimal current demand for this specific antibiotic among state and local buyers.

Recent activity spans Florida, Minnesota, Texas, and Florida municipalities, with issuing bodies including county health departments, state HHS commissions, and city fire services. The Seminole County naloxone procurement (due July 26, 2023, though posted June 30, 2026) is an IFB for 1,900 units annually with quarterly deliveries; the Minnesota MMCAP RFP (due March 26, 2026) establishes multi-vendor contracts for generic pharmaceuticals across state and local facilities with awards effective July 1, 2026; and the Tampa medical supplies IFB (due March 13, 2026) is a sheltered Small Local Business Enterprise opportunity for $700,000 estimated value serving the Fire Department Rescue Division. The code exhibits no clear concentration of sulfamoxole-specific demand and does not represent a coherent procurement category under current state and local activity.